MedKoo Cat#: 406755 | Name: MI-463
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MI-463 is a potent menin-MLL inhibitor with IC50=15.3 nM and Kd=9.9 nM. MI-463 shows its profound effects in MLL leukemia cells and substantial survival benefit in mouse models of MLL leukemia. Pharmacologic inhibition of the menin-MLL interaction represents an effective treatment for MLL leukemias in vivo and provide advanced molecular scaffold for clinical lead identification. Chromosomal translocations affecting mixed lineage leukemia gene (MLL) result in acute leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is dependent on their interaction with menin, providing basis for therapeutic intervention.

Chemical Structure

MI-463
MI-463
CAS#1628317-18-9

Theoretical Analysis

MedKoo Cat#: 406755

Name: MI-463

CAS#: 1628317-18-9

Chemical Formula: C24H23F3N6S

Exact Mass: 484.1657

Molecular Weight: 484.55

Elemental Analysis: C, 59.49; H, 4.78; F, 11.76; N, 17.34; S, 6.62

Price and Availability

Size Price Availability Quantity
5mg USD 300.00 2 Weeks
10mg USD 550.00 2 Weeks
25mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MI-463; MI 463; MI463;
IUPAC/Chemical Name
4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile
InChi Key
DZACSLYTXLZAAF-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H23F3N6S/c1-14-15(2-3-21-19(14)8-17(11-28)31-21)12-33-6-4-16(5-7-33)32-22-20-9-18(10-24(25,26)27)34-23(20)30-13-29-22/h2-3,8-9,13,16,31H,4-7,10,12H2,1H3,(H,29,30,32)
SMILES Code
CC1=C2C(NC(C#N)=C2)=CC=C1CN(CC3)CCC3NC4=C(C=C(CC(F)(F)F)S5)C5=NC=N4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
In vitro activity:
MI‑463 at a double‑digit nM concentration markedly decreased the viable number of OVCAR‑8 ovarian cancer cells for 3 days. Ferrostatin‑1 (a ferroptosis inhibitor) almost completely abrogated the MI‑463‑induced decrease in viable cell numbers. Reference: Int J Oncol. 2020 Oct;57(4):1057-1071. https://pubmed.ncbi.nlm.nih.gov/32945449/
In vivo activity:
Importantly, treatment with either compound strongly delayed leukemia progression as reflected by a substantial survival benefit in MLL-AF9 leukemia mice when MI-463 and MI-503 were applied as single agents (Figure 5A). The median survival of MLL-AF9 leukemia mice was increased by ~70% and ~45% upon treatment with MI-463 and MI-503, respectively (Figure 5A), demonstrating their pronounced effects in blocking MLL leukemia progression in vivo. Reference: Cancer Cell. 2015 Apr 13;27(4):589-602. https://pubmed.ncbi.nlm.nih.gov/25817203/
Solvent mg/mL mM comments
Solubility
DMSO 110.5 228.05
Ethanol 22.0 45.40
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 484.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kato I, Kasukabe T, Kumakura S. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Int J Oncol. 2020 Oct;57(4):1057-1071. doi: 10.3892/ijo.2020.5116. Epub 2020 Aug 28. PMID: 32945449. 2. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. PMID: 25817203; PMCID: PMC4415852. 3. Fedor Z, Szentkirályi-Tóth A, Nagy G, Szimrók Z, Varga E, Pászti A, Pászti Z, Jerzsele Á, Pilgram O, Steinmetzer T, Mátis G, Neogrády Z, Pászti-Gere E. Interspecies Comparisons of the Effects of Potential Antiviral 3-Amidinophenylalanine Derivatives on Cytochrome P450 1A2 Isoenzyme. Vet Sci. 2022 Mar 23;9(4):156. doi: 10.3390/vetsci9040156. PMID: 35448654; PMCID: PMC9027957.
In vitro protocol:
1. Kato I, Kasukabe T, Kumakura S. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Int J Oncol. 2020 Oct;57(4):1057-1071. doi: 10.3892/ijo.2020.5116. Epub 2020 Aug 28. PMID: 32945449. 2. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. PMID: 25817203; PMCID: PMC4415852.
In vivo protocol:
1. Fedor Z, Szentkirályi-Tóth A, Nagy G, Szimrók Z, Varga E, Pászti A, Pászti Z, Jerzsele Á, Pilgram O, Steinmetzer T, Mátis G, Neogrády Z, Pászti-Gere E. Interspecies Comparisons of the Effects of Potential Antiviral 3-Amidinophenylalanine Derivatives on Cytochrome P450 1A2 Isoenzyme. Vet Sci. 2022 Mar 23;9(4):156. doi: 10.3390/vetsci9040156. PMID: 35448654; PMCID: PMC9027957. 2. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. PMID: 25817203; PMCID: PMC4415852.
1: Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. PMID: 25817203; PMCID: PMC4415852. 2: Kato I, Kasukabe T, Kumakura S. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Int J Oncol. 2020 Oct;57(4):1057-1071. doi: 10.3892/ijo.2020.5116. Epub 2020 Aug 28. PMID: 32945449.